
Does cancer vaccine have an effect on Lynch syndrome?
Checked
Posts and adverts say that cancer vaccines can help prevent cancers in people with Lynch syndrome, an inherited condition that raises the risk of bowel and other cancers.
It is not proven that cancer vaccine has an effect on Lynch syndrome.
What studies show
As of , no study proves that cancer vaccine has an effect on Lynch syndrome. We found 18 published papers on cancer vaccine and Lynch syndrome. They were published between 2016 and 2026. 4 of them are studies in people. At least 183 people took part. 2 of them were fair tests in which chance decided who got it and who did not. 3 were studies in animals, and none was only in cells in the lab. 6 papers are reviews that sum up other studies.
Trials in people
A 2026 phase 1b/2 trial of the Nous-209 vaccine (45 Lynch syndrome carriers, all on the vaccine, no control group) looked at safety and immune response, not at whether cancers were prevented. The authors report no serious side effects linked to the vaccine; the most common were injection-site reactions and fatigue. The authors also report immune responses against the vaccine's targets in all 37 people who could be checked. A 2026 paper describes the design and early report of a randomised, placebo-controlled phase IIb trial (TRIAD5-Plus) of an adenovirus vaccine plus an immune booster in Lynch syndrome; it plans to randomise 138 people and check for bowel growths by colonoscopy at weeks 52 and 104. In its first safety phases, 20 people received the vaccine series; most side effects were mild (grade 1), and the trial was still ongoing, so no result on cancer or growth rates is reported.
Other studies in people
A 2020 phase I/IIa trial gave a frameshift-peptide vaccine to 22 people who had already had a bowel cancer with mismatch repair deficiency, the fault behind Lynch syndrome. The authors report immune responses in all patients vaccinated as planned and no severe side effects caused by the vaccine; it was a small trial with no placebo group.
Reviews
Several reviews describe vaccines against the shared abnormal proteins that mismatch repair-deficient tumours make as a promising way to prevent cancer in people with Lynch syndrome. A 2016 review sets out the immune biology that led to this idea and proposes preventive vaccines as a research direction.
In animals
In a 2021 mouse model of Lynch syndrome, a vaccine made of four frameshift peptides is reported to give protective immunity, with smaller tumour burden and better survival. A 2022 study in mice with the same kind of mismatch repair fault found a single vaccine peptide that prevented tumours or slowed their growth in immunised mice. A 2024 mouse study of a tumour-lysate liposome vaccine combined with an anti-PD-L1 antibody reported slower progression of Lynch syndrome-associated colon cancer than either approach alone.
Other papers
A 2024 analysis of tumour and precancer samples from 43 Lynch syndrome carriers found shared mutated targets for a vaccine, and 65% of the 100 top predicted targets triggered immune responses in lab tests. A 2026 analysis of 73 Lynch syndrome tumours found that the targets of the Nous-209 vaccine were present in both first and later cancers, supporting the idea behind the vaccine. A 2018 report on tumour samples from one patient found three vaccine-candidate peptides that triggered immune cells in the lab. A 2026 news piece summarises the Nous-209 trial; it is a comment, not a new study.
What this means for you
Our verdict: Unproven.
Do not decide anything about cancer vaccine because of one story or post. A study in people is not proof that it helps you. If you are thinking about cancer vaccine, talk to your doctor first.
This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.
We searched 18 scientific databases for research from the last 10 years (since 2016. nov. 17.).
Sources
- Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nat Med 2026. Study in people. PubMed
- Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). Front Immunol 2026. Randomised trial. PubMed
- NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome. Mol Cancer Ther 2026. Other paper. PubMed
- Neoantigen Vaccine Spurs Broad Immune Responses. Cancer Discov 2026. Other paper. PubMed
- Immunoprevention Strategies for Colorectal Cancer in Lynch Syndrome Carriers. Cancer J 2024. Review. PubMed
- Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer. ACS Biomater Sci Eng 2024. In animals. PubMed
- Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention. Gastroenterology 2024. Other paper. PubMed
- Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. Front Oncol 2023. Review. PubMed
- Vaccines for immunoprevention of DNA mismatch repair deficient cancers. J Immunother Cancer 2022. Review. PubMed
- On the development of a neoantigen vaccine for the prevention of Lynch Syndrome. Int J Cancer 2022. In animals. PubMed
- Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Front Immunol 2021. Review. PubMed
- Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology 2021. In animals. PubMed
- A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial. Clin Cancer Res 2020. Study in people. PubMed
- A cancer vaccine approach for personalized treatment of Lynch Syndrome. Sci Rep 2018. Other paper. PubMed
- The Immune Biology of Microsatellite-Unstable Cancer. Trends Cancer 2016. Review. PubMed